Croatia's Mavota and Pliva acquire Medika stake
This article was originally published in Scrip
Croatia's financial services supervisory agency (HANFA) has approved the acquisition of the remaining stake in Medika, a local pharmaceutical wholesaler, by a group of shareholders led by local firm Mavota. The shareholders, who currently have a 63% stake in Medika, have offered Kn7,310 ($1.30) per share, its average price over the past three months.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.